Biomedical CEOs in California continue to see a burdensome FDA regulatory environment as a major hinderance to the industries growth, according to preliminary results of a CEO survey conducted by the California Healthcare Institute, BayBio and PwC.
In a preview of a broader survey to be released in February, 8 in 10 CEOs said that the current FDA regulatory approval process "has slowed the growth of their organization" and is among one of the biggest threats to the growth of the med-tech sector in the U.S.